Altimmune, Inc. - Common Stock (NQ:ALT)

2.735 -0.025 (-0.91%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Altimmune, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Altimmune Details Pemvidutide’s Path Toward a Liver-Disease Franchise ↗

October 01, 2026

Altimmune (NASDAQ:ALT) executives outlined the company’s strategy to build a liver-disease franchise around pemvidutide, a dual glucagon/GLP-1 agonist being developed for metabolic...

Via MarketBeat

Altimmune Q2 Earnings Call Highlights ↗

August 12, 2026

Altimmune (NASDAQ:ALT) said it has initiated patient enrollment in its global Phase III PERFORMA trial of pemvidutide for metabolic dysfunction-associated steatohepatitis, or MASH, while advancing...

Via MarketBeat

Topics Artificial Intelligence Earnings

Altimmune’s Pemvidutide Meets Phase II Endpoint in Alcohol Use Disorder Trial ↗

July 28, 2026

Altimmune (NASDAQ:ALT) reported positive top-line results from its Phase II RECLAIM trial evaluating pemvidutide in adults with moderate to severe alcohol use disorder, or AUD, with the company saying...

Via MarketBeat

Altimmune Sets Pemvidutide’s Phase 3 MASH Playbook as AUD Data Near ↗

June 10, 2026

Altimmune (NASDAQ:ALT) management used an appearance at the Goldman Sachs Global Healthcare Conference to outline the company’s focus on pemvidutide, its lead metabolic and liver disease drug...

Via MarketBeat

Altimmune Inc (NASDAQ:ALT) Reports Q4 Earnings Miss Amid Key Pipeline Milestones ↗

March 05, 2026

Via Chartmill

Topics Earnings

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

What 5 Analyst Ratings Have To Say About Altimmune ↗

August 13, 2025

Via Benzinga

Altimmune Touts Pemvidutide Momentum Ahead of Phase 3 MASH Trial ↗

June 04, 2026

Altimmune (NASDAQ:ALT) executives said the company is preparing to begin enrolling patients in the second half of the year for a Phase 3 trial of pemvidutide in metabolic dysfunction-associated...

Via MarketBeat

Altimmune (ALT) Q1 2026 Earnings Transcript ↗

May 13, 2026

Altimmune (ALT) Q1 2026 Earnings Transcript

Via The Motley Fool

Altimmune Q1 Earnings Call Highlights ↗

May 13, 2026

Altimmune (NASDAQ:ALT) said it has strengthened its balance sheet and is preparing to begin a global Phase 3 trial of pemvidutide in metabolic dysfunction-associated steatohepatitis, or MASH, in the...

Via MarketBeat

Topics Earnings

What's going on in today's pre-market session ↗

April 23, 2026

Via Chartmill

Stay updated with the stocks that are on the move in today's after-hours session. ↗

April 22, 2026

Via Chartmill

ALT Stock Drops On Wider-Than-Expected Q4 Loss: Retail Voices Hopes For Deal To Alleviate Cash Concerns ↗

March 05, 2026

CFO says company continues to be “strategic and opportunistic” in approach to securing capital needed for late-stage MASH trial.

Via Stocktwits

Altimmune (ALT) Q4 2025 Earnings Call Transcript ↗

March 05, 2026

Altimmune (ALT) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Forget Altimmune: This Proven Obesity‑Drug Giant Is the Better Weight‑Loss Play ↗

February 26, 2026

The maker of Wegovy hasn't said its last words just yet.

Via The Motley Fool

Nasdaq, S&P 500 Futures Edge Higher Ahead Of Fed Decision, Mag 7 Earnings Kick Off: Why NVDA, ASML, ALT, AI, UUU Are On Traders' Radar Today ↗

January 28, 2026

Retail sentiment on major ETFs such as SPY and QQQ turned ‘extremely bearish’ on Stocktwits.

Via Stocktwits

Topics Artificial Intelligence ETFs Economy

ALT Stock Surges Toward Sixth Straight Day Of Gains: Retail Bets A Buyout Is On The Horizon ↗

January 27, 2026

Altimmune plans to raise $75 million via a direct offering to bankroll its Phase 3 MASH trial, easing near-term funding risk.

Via Stocktwits

Nasdaq, S&P 500 Futures Subdued Ahead Of PMI Data: Why INTC, TSLA, NFLX, VST, MOVE Are On Traders' Radar Today ↗

January 23, 2026

Retail sentiment on Stocktwits for SPY and QQQ remained ‘bearish’.

Via Stocktwits

Topics ETFs Government Lawsuit

ALT Stock Rallies 4% — What Does Retail Think? ↗

January 22, 2026

Earlier this month, Altimmune said the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for pemvidutide for the treatment of patients with metabolic...

Via Stocktwits

Why Are Investors Looking At Altimmune Stock? ↗

January 05, 2026

Shares of Altimmune, Inc. (NASDAQ: ALT) are rising Monday after the FDA granted Breakthrough Therapy Designation for Pemvidutide.

Via Benzinga

Altimmune Receives FDA’s Breakthrough Therapy Designation For Its Liver Disease Drug ↗

January 05, 2026

The FDA decision was based on 24-week data from the IMPACT Phase 2b trial, showing considerable MASH resolution without worsening fibrosis.

Via Stocktwits

Altimmune Stock Soars Over 10% Premarket On Positive Mid-Stage Data For Liver Disease Treatment Drug ↗

December 19, 2025

New 48-week data showed its dual-action drug outperformed placebo across key non-invasive liver tests.

Via Stocktwits

Altimmune Stock Attracts Strong Retail Buzz As Investors Count Down To 48-Week Data For Its Fatty Liver Treatment ↗

November 17, 2025

Retail traders focused on AI-driven biopsy findings and clearer dose-response exuded increased confidence in pemvidutide’s potential.

Via Stocktwits

Altimmune Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗

October 10, 2025

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

September 29, 2025

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Radian Group, Intel, Nanobiotix, CrowdStrike And Other Big Stocks Moving Higher On Thursday ↗

September 18, 2025

Via Benzinga

Viking Therapeutics Plummets as Oral Obesity Drug Trial Raises Tolerability Concerns

August 19, 2025

San Diego, CA – Viking Therapeutics (NASDAQ: VKTX) experienced a dramatic stock decline today following the release of disappointing clinical trial results for its highly anticipated oral tablet...

Via MarketMinute

These Analysts Slash Their Forecasts On Altimmune Following Q2 Results ↗

August 13, 2025

Via Benzinga

Altimmune Q2 FY2025 Earnings Call Transcript ↗

August 12, 2025

Altimmune Q2 FY2025 earnings call transcript

Via Benzinga

Topics Earnings

Earnings Scheduled For August 12, 2025 ↗

August 12, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.